Paclitaxel pharmacodynamics: Application of a mechanism-based neutropenia model

Biopharmaceutics and Drug Disposition

Volumn 22, Issue 6, 2001, Pages 251-261

  Fetterly, Gerald J ^a,b   Tamburlin, Judith M ^a   Straubinger, Robert M ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Bone marrow; Cancer; Neutropenia; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CREMOPHOR; LIPOSOME; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BONE MARROW CELL; BONE MARROW SUPPRESSION; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG FORMULATION; HEMATOLOGIC DISEASE; LEUKOCYTE COUNT; MALE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; RAT; SIMULATION; STEM CELL; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BLOOD CELL COUNT; BONE MARROW CELLS; ERYTHROID PROGENITOR CELLS; LIPOSOMES; MALE; NEUTROPENIA; NEUTROPHILS; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0035693077     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.283     Document Type: Article

References (36)

1. Paclitaxel plus ifosfamide in advanced ovarian cancer: Results of a phase I study
2. Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: An interim analysis of a phase II multicenter study
3. Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines
4. Pharmacologic study of 3-hour 135mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer
5. Future directions of paclitaxel-based therapy of breast cancer
6. Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations
7. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel
8. Therapy for Kaposi's sarcoma: Recent advances and experimental approaches
9. Possible mechanisms of paclitaxel-induced apoptosis
10. A common pharmacophore for cytotoxic natural products that stabilize microtubules
11. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations
12. Taxol suppresses dynamics of individual microtubules in living human tumor cells
13. The mode of action of taxol: Apoptosis at low concentration and necrosis at high concentration
14. Hypersensitivity reactions from taxol
15. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study
16. Clinical toxicities encountered with paclitaxel (Taxol)
17. Paclitaxel pharmacokinetics and pharmacodynamics
18. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
19. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion
20. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression
21. Indirect-response model for the time course of leukopenia with anticancer drugs
22. Passive mechanical behavior of human neutrophils: Effects of colchicine and paclitaxel
23. Comparison of four basic models of indirect pharmacodynamic responses
24. Novel taxol formulations: Preparation and characterization of taxol-containing liposomes
25. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins
26. A program package for simulation and parameter estimation in pharmacokinetic systems
27. Pharmacokinetic/pharmacodynamic models for corticosteroid receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a receptor/gene-mediated mechanism
28. Can pharmacokinetic and pharmacodynamic studies improve cancer chemotherapy?
29. Pharmacologically guided phase I clinical trials based upon preclinical drug development
30. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels
31. Pharmacologically based phase I trials in cancer chemotherapy
32. Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: Relations with disease activity, antibodies to double stranded DNA, and neutropenia
33. Pharmacodynamics of immediate and delayed effects of paclitaxel: Role of slow apoptosis and intracellular drug retention
34. 3H)-thymidine labeling of rat tibial bone marrow in vivo
35. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model
36. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia